The ethane sulfonate (ESA) metabolite of the herbicide alachlor is formed in soil by microbial action. The present studies were conducted to assess the toxicity of ESA and provide a base set of data for risk assessment. ESA did not induce chromosomal effects in a mouse bone marrow micronucleus assay following acute administration. Administration of ESA to rats in drinking water at concentrations of 200, 2000, and 10,000 ppm for 91 days elicited biologically significant indications of toxicity only at the high-dose level (1002 mg/kg/day). The observed responses included decreases in body weights and food consumption as well as effects on clinical chemistry values. Many of the changes appeared to be due to decreased palatability of the drinking water. There were no ESA-induced gross pathology findings, organ weight changes, or microscopic lesions. ESA did not produce any adverse effects in pregnant rats or their offspring even at 1000 mg/kg/day, the highest dose tested. These findings show that the subchronic and developmental toxicity of ESA are low. Furthermore, comparison of results from studies with alachlor and its metabolite shows that the toxicity of ESA is substantially lower. Margins of exposure for ESA range from 133,824 to 2,573,529 even using worst-case estimates of exposure, indicating that the metabolite poses little risk of producing adverse effects at the very low levels occasionally encountered. These results and accompanying analyses support the conclusion that ESA is not of toxicological concern, o 1°% society or
Toxicology
The tertiary ethane sulfonate (ESA) metabolite of alachlor, or 2-[(2,6-diethylphenyl) (methoxymethyl)]-amino-2-oxoethanesulfonic acid, is formed by soil microbes via glutathione conjugation and subsequent oxidative metabolism. The chemical structure of ESA (Fig. 1 ) differs from that of alachlor at one position where the chlorine atom of the parent molecule has been replaced by a sulfonic acid moiety. Alachlor is a selective herbicide used for preplant and early postemergent control of grass and small-seeded broadleaf weeds in corn and other crops. The results of an extensive well water monitoring survey have shown that alachlor is rarely found in groundwater and then only at very low levels (Holden and Graham, 1992) . ESA has been detected in private rural wells in agricultural areas of Indiana (Baker et al., 1993) . Follow-up analyses to quantify ESA in those well water samples with detections showed that the highest levels generally ranged from 0.007 to 0.017 ppm ESA, with one sample containing 0.023 ppm. ESA has also been found in some rural Wisconsin wells, with the vast majority of detections ranging from 0.001 to 0.012 ppm (DATCP, 1994) . Further investigation has shown that almost all such ESA detections occur in wells which have high levels of nitrate and other agricultural chemicals, indicating that the wells are unusually vulnerable to contamination from surface-applied materials.
ESA is a polar, water-soluble molecule. A metabolism study in lactating goats showed that ESA was rapidly excreted as unchanged test material, primarily in the feces (Klemm et al., 1985) . There was no accumulation of ESA in milk or edible tissue. Based on these characteristics, it was anticipated that the toxicity of ESA would be relatively low. The oral LD50 of ESA in rats was subsequently shown to be greater than 6000 mg/kg, indicating that its acute toxicity is, in fact, significantly lower than that of parent alachlor (LD50 = 930-1350) (Monsanto, 1995) . Like alachlor, ESA was not mutagenic in Ames assays employing four test strains of 5. typhimurium (Kier, 1984) . Thus, the preliminary metabolic and toxicologic profiles did not provide any indication that ESA would be of toxicological concern.
Given the occasional detection of ESA in well water samples, albeit at relatively low levels, it was decided that additional toxicological information should be developed for this substance. The present work was undertaken to study the potential subchronic, developmental, and genetic toxicity of ESA. The toxicity of ESA was compared to that of alachlor, for which a comprehensive toxicology database has been developed. In addition, no-effect levels from the ESA studies were compared to levels of human exposure. These assessments were done to determine potential risks to humans and to evaluate the need for additional studies. 
MATERIAL AND METHODS

Test Material
ESA was synthesized in several batches from alachlor. After the batches were dried, they were combined into one lot and the powder was mixed thoroughly using a fluidization technique. The blended lot was shown to contain 90.7% ESA and 6.6% water
Animals and Husbandry
Male and female Fischer 344 rats (Charles River Laboratories, Inc., Raleigh, NC) were used in the subchronic drinking water study. At the beginning of the study, animals were approximately 8 weeks of age. Male and female Spragtie-Dawley rats were obtained from Charles River Breeding Laboratories (Portage, MI) for use in the developmental toxicity study. At study initiation, the animals were approximately 12 weeks old. For the micronucleus assay, male and female CD-I mice were supplied by Charles River Breeding Laboratories (Portage, MI); the animals were 7 to 12 weeks old at receipt. Animals from all studies were housed individually (except during mating in the developmental toxicity study) and maintained under standard laboratory conditions.
Subchronic Toxicity Study
Test material administration and analysis. ESA was administered to rats in drinking water via individual bottles. The test material concentration was adjusted to account for the 90.7% purity. Water intake was measured once or twice weekly throughout the study to allow calculations of test material intake. The homogeneity of low-and high-dose ESA water solutions was verifed prior to the start of the study, and the stability of ESA in water was verified both prior to and during the study. In addition, drinking water solutions prepared during the study were analyzed to verify ESA concentrations at all dose levels.
Experimental design. Three groups of 10 male and 10 female rats received ESA in drinking water at target concentrations of 200, 2000, and 10,000 ppm for 91 days. The concentrations were selected based on results from a 28-day dose range-finding study conducted at levels up to 20,000 ppm. An additional group of 10 males and 10 females served as controls and received untreated drinking water under the same experimental conditions. All animals were observed daily for mortality and clinical signs of toxicity. Body weights and food consumption were determined weekly. Bimicroscopic and indirect ophthalmoscopic examinations were performed on all animals prior to and at the end of the study.
Hematology and clinical chemistry. Blood was collected from fasted rats at the end of the study for evaluation of hematology and clinical chemistry parameters. The blood samples were obtained via ocular bleeding while the animals were under light isoflurane anesmesia. The following hematological parameters were evaluated using a Coulter S Plus IV hematology analyzer: total leukocyte, erythrocyte, and platelet counts, hematocnt, hemoglobin concentration, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. Differential leukocyte counts were conducted by microscopic examination of Wrightstained blood smears. Reticulocytes were also counted by direct inspection using the Miller Disc Reticle following staining of cells with methylene blue.
The following clinical chemistry parameters were evaluated using a Beckman Synchron CX-5 chemistry analyzer alanine aminotransferase (ALT), albumin, albumin/globulin ratio (calculated), alkaline phosphatase (ALP), calcium, cholesterol, aspartate aminotransferase (AST), creatinine, chloride, glucose, globulin (calculated), potassium, phosphorus, sodium, totaJ bilirubin, total serum protein, triglycerides, and blood urea nitrogen.
Pathology. At the scheduled termination, animals were euthanized by carbon dioxide inhalation and necropsied. Organ weights were obtained for the liver, kidneys, testes, ovaries, adrenal glands, thyroid/parathyroid, brain, and heart; organ-to-brain weight ratios were calculated. The following organs and tissues, or representative samples thereof, were preserved in 10% neutral buffered Formalin: accessory genital organs, adrenals, aorta, brain, cecum, colon, duodenum, esophagus, exorbital lachrymal glands, eyes, femur, gross lesions, heart, ileum, jejunum, kidneys, liver, lungs, mammary gland, mesenteric lymph node, nasopharyngeal turbinates, pancreas, peripheral nerve (sciatic), pituitary, rectum, salivary glands, skeletal muscle, spinal cord, spleen, sternum with bone marrow, stomach, testes/ovaries, thymus, thyroid/parathyroid, trachea, and urinary bladder. At the time of necropsy, the nasal turbinates were completely flushed with 10% neutral buffered Formalin, and the entire head was then immersed in fixative for subsequent histological processing. Tissues collected at necropsy from control, highdose, and all animals found dead during the study, as well as the lungs, kidneys, and gross lesions from all low-and mid-dose animals, were processed for histological examination. The tissues were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined by light microscopy.
Developmental Toxicity Study
Test material administration and analysis. ESA was dissolved in corn oil and administered by oral gavage. Samples of the test material from all dose groups were analyzed to verify concentrations prior to the initiation of dosing. Homogeneity of low-and high-dose solutions was verified by analyzing aliquots drawn from the top, middle, and bottom portions of the dosing container. Aliquots were collected from the low-and high-dose solutions prior to the initiation of dosing and subsequently analyzed at the end of the dosing period to verify stability.
Experimental design and observations. ESA was administered by gavage to three groups of 25 bred female rats once daily from Gestation Days 6 through 15. The dosage levels were 150, 400, and 1000 mg/kg/day. The 1000 mg/kg/day level is the limit dose for developmental toxicity studies (U.S. EPA, 1982) . A concurrent control group, also consisting of 25 bred females, received com oil only on the same days of gestation. All females were observed twice daily for moribundity and mortality. Detailed clinical observations were recorded daily for each animal throughout gestation (Days 0 through 20) Animals were also observed for signs of toxicity at the time of dosing and approximately 1 hr following dosing. Maternal body weights and food consumption were recorded on Gestation Days 0, 6, 9, 12, 16, 18, and 20.
Terminal investigations. All maternal animals were euthanized by carbon dioxide inhalation on Gestation Day 20. The thoracic, abdominal, and pelvic cavities were opened and examined. The uterus and ovaries were excised. The number of corpora lutea on each ovary was recorded. The trimmed uterus was weighed and opened; the number and location of all fetuses, early and late resorptions, and the total number of implantation sites were recorded. The individual uterine distribution of implantation sites was documented. Uteri with no macroscopic evidence of nidation were excised, opened, and subsequently placed in 10% ammonium sulfide for detection of early implantation loss. The liver, kidneys, and spleen from each dam were removed and weighed.
Each fetus was sexed, weighed, and tagged for identification. A detailed external examination of each fetus was conducted. Crown-rump measurements were recorded (as appropriate) for late resorptions. The viscera of each fetus, including the heart and major blood vessels, was dissected and examined. Fetal kidneys were examined and graded for renal papillae development. Heads from approximately one-half of the fetuses from each litter were placed in Bouin's fixative for subsequent soft-tissue sectioning and examination. Heads from the remaining one-half of the fetuses were examined by a midcoronal slice. All carcasses were eviscerated, fixed in alcohol, and stained with Alizarin Red S; skeletal examinations were conducted under low-power magnification using a stereomicroscope. External, visceral, and skeletal findings for each fetus were recorded as developmental variations or malformations.
Micronucleus Study
Test material administration and analysis. ESA was administered by oral gavage as a single dose in deionized water. The ESA concentration of the high-dose solution was confirmed by UV-spectrophotometric analysis on the day of dosing. The homogeneity of ESA in this dosing solution was verified. Analysis to confirm stability of the neat test material was also performed.
Experimental design and investigations. ESA was administered to groups of 10 male mice at dose levels of 500, 1000, and 2000 mg/kg. The 2000 mg/kg dose level is the limit dose currently recommended for m vivo genetic toxicology testing (OECD, 1994; Tice and Shelby, 1994) . A control group of 10 mice received only deionized water. Five mice from each dose level and the vehicle control group were euthanized 24 and 48 hr after dosing. An additional group of 5 mice was administered cyclophosphamide and euthanized 24 hr after dosing to serve as a positive control.
At necropsy, both femurs were removed, the proximal ends of each were opened, and the marrow was flushed into a centrifuge tube with approximately 2 ml fetal bovine serum. After centrifugation to remove the serum, a portion of the marrow sediment was smeared onto a clean slide. Bone marrow smears from all animals were fixed, stained, and examined microscopically. Two thousand polychromatic erythrocytes (PCEs) were scored for the presence of micronuclei. The PCE-to-mature erythrocyte ratio was measured for 1000 erythrocytes per animal as an indicator of bone marrow toxicity.
Statistical Methods
Subchronic toxicity study. Continuous data, including body weights, weight gain, food and water consumption, organ weights, and clinical pathology determinations, were analyzed by a one-way analysis of variance (ANOVA) (Snedecor and Cochran, 1967) . When significant differences were observed with ANOVA, control-to-treatment group comparisons were performed using Dunnett's test (Dunnett, 1955) or a modified Dunnett's test (Dunlap et al., 1981) .
Developmental toxicity study. Corpora lutea, total implantations, viable fetuses, fetal body weights, maternal body weights and weight changes, maternal net body weight changes, gravid uterine weights, maternal food consumption, and organ weights were evaluated by ANOVA followed by Dunnett's test (Dunnett, 1955) . The numbers of fetuses and litters with variations and malformations were analyzed by Fisher's exact test. Early and late resorptions, dead fetuses, and postimplantation losses were compared using the Mann-Whitney U test, while fetal sex ratios were analyzed using a \ 2 test with Yates' correction factor. All analyses were conducted using two-tailed tests for a minimum significance level of 5% comparing each treated group to the vehicle control group. All statistical tests were performed using BMDP Biomedical Computer Programs (Dixon and Brown, 1979) Micronucleus study. Micronucleated PCE frequencies observed for each animal were transformed as the square root prior to analysis (Snedecor and Cochran, 1967; MacGregor et al., 1987) . PCE/total erythrocyte ratios were not transformed. A Dunnett's test (one-sided) was used for comparison of treatment groups and positive control values with vehicle control values.
RESULTS
Subchronic Toxicity Study
Water intake was significantly reduced in 10,000-ppm males and females (51 and 37% below control values, respectively) during the first week of the study (Table 1) ; these decreases were believed to be due to decreased palatability of the drinking water solutions. The decreased water intake during the first week was accompanied by the appearance of various clinical signs (e.g., rough coat, dehydration, emaciation, dark material around eyes) as well as by significant decreases in mean body weight and food consumption. One male rat, which exhibited severe signs, was later found dead on Study Day 13. During the second week of the study, high-dose animals exhibited increases in both water intake and body weight gain, further indicating that the adverse effects observed earlier were attributable to an initial decrease in drinking water palatability. Body weight gain in 10,000-ppm males remained elevated above the control level during Week 3. No other changes in body weight gain were noted in 10,000-ppm animals for the remainder of the study. In contrast, water consumption remained elevated in 10,000-ppm males throughout the study.
Water intake was also reduced in 2000-ppm males and females (15 and 14%, respectively) during Week 1. However, these decreases resulted in only a slight reduction in mean weight gain in males (not statistically significant), while no change was noted in female body weights. There were no other treatment-related changes in water consumption or body weight gain in 2000-ppm males or females throughout the rest of the study, nor in 200-ppm males or females at any time during the study. Occasional decreases in mean body weight and/or weight gain were noted in females at the 200-and 2000-ppm levels, but these differences did not follow any pattern which indicated a relationship to treatment. Moreover, no such changes were seen in the 1-month dose range-finding study conducted at ESA concentrations of 700, 2000, and 7000 ppm. Therefore, it was concluded that these differences were spurious and not related to administration of the test material.
Paraocular changes, such as dark material and hair loss around the eyes, were noted in both control and treated animals. Some of these findings may have been treatment-related in high-dose animals. However, interpretation is complicated by the fact that the same symptoms are observed in animals that have been stressed by water deprivation, which occurred in this study due to the decreased water palatability. None of the paraocular observations were significantly elevated in low-and mid-dose animals, and the incidences did not follow any doseresponse patterns in these groups. More importantly, there were no correlative ophthalmological changes nor histopathologicaJ lesions at any dose level, thus indicating no underlying testmaterial-related pathology in ocular or surrounding tissues. Spontaneous ocular problems are common in the F-344 rat due to genetic and exogenous factors, such as viral infection, and these problems result in the types of symptoms observed in this study. It was noted that several animals in the study had dacryoadenitis, the most common cause of which is the sialodacryoadenitis virus. It was concluded, therefore, that the occurrences of paraocular clinical signs were due to one or more of the incidental factors which are active in the F-344 rat.
The total leukocyte count was increased (19% above control) in females from the 10,000-ppm group (Table 2 ). There were very slight but statistically significant decreases (~3-5% below controls) in red blood cell counts (RBC), hemoglobin (HG), and hematocrit (HCT) in 10,000-ppm males; there was also a statistically significant increase (~2% above control) in mean corpuscular hemoglobin. Smaller decreases (-2-4%) in RBC, HG, and HCT values were also noted in males from the 2000-ppm dose group. These decreases were minimal and exhibited very little or no dose response over the 50-fold range of doses tested, and there were no other correlative changes (e.g., increased reticulocytes, hemosiderin deposition, hemolysis). In addition, examination of historical control data showed that the control RBC, HG, and HCT values exceeded the historical control range, indicating that the apparent increases in treated animals were probably due to incidentally higher values in control males.
The following statistically significant changes in clinical chemistry values (Table 3) were noted in 10,000-ppm males: decreased glucose (~11%) and increased total bilirubin (~24%) and phosphorus (~11%). There were also statistically significant reductions in albumin in 2000-and 10,000-ppm males (~2.7 and 4.0%, respectively). However, the lack of any real decrement over a wide span of doses does not support a treatment-related effect, and the very small degree of change indicates that the apparent differences, if real, are not biologically significant.
In the 10,000-ppm male that died during the study, remarkable gross necropsy findings were reduced body fat, reddening of the stomach and duodenum, and a small thymus gland. In surviving animals, there were no treatment-related gross pathology findings, organ weight changes (Table 4) , or histopathological lesions. Thus, there was no indication of target organ toxicity.
Developmental Toxicity Study
All animals survived to the scheduled necropsy on Gestation Day 20. The predominant clinical sign was rales, which was noted occasionally in only a few animals from the 1000 mg/ kg/day group. There were no adverse effects on mean gestation body weights (Table 5) , body weight gains, gravid uterine weights, net body weights, or net body weight gains at any dose level. Food consumption in the treated groups was comparable to the control group values throughout gestation.
At the scheduled necropsy, no treatment-related internal findings were observed at any dose level. Mean liver, kidney, and spleen weights in all treated groups were comparable to the control group values (Table 5) . Intrauterine growth and survival, as measured by mean postimplantation loss, viable litter size, fetal body weights, and fetal sex ratios, as well as numbers of corpora lutea and implantation sites, were all unaffected by administration of ESA (Table 6 ). The mean fetal body weight in the 400 mg/ kg/day group was slightly reduced. However, the 1000 mg/ kg/day group value was comparable to that of the control group. Therefore, the slight reduction in the mid-dose group was not considered treatment-related. There was no compound-related increase in external, visceral, or skeletal variations or malformations (Table 6 ). Thus, administration of ESA to pregnant rats did not produce any evidence of developmental toxicity at dose levels up to and including 1000 mg/kg/day.
Micronucleus Study
There were no statistically significant decreases in mean PCE/total erythrocyte ratios for any of the ESA-treated groups. Analysis of the micronucleated PCE data showed no statistically significant increase in mean micronucleated PCE frequency compared to concurrent controls for any group given ESA (data not shown). The positive control material, cyclophosphamide, produced the expected positive response in micronucleated PCE frequency, demonstrating the adequacy of the experimental conditions.
DISCUSSION
ESA Toxicity Studies
Administration of ESA at 10,000 ppm in the drinking water for 91 days resulted in various effects on body weight, food consumption, and clinical chemistry values. However, it appeared that many of these changes were due to decreased palatability and consumption of the drinking water solutions during Study Week 1 rather than to direct toxicity of ESA. Water intake was also reduced in 2000-ppm animals during the first week, but this was accompanied by only a marginal and transient decrease in weight gain in males. A small, equivocal change in the albumin value in 2000-ppm males was considered biologically insignificant. Based on these results, it was concluded that 2000 ppm (182 mg/kg/day) represents a no-observed-adverse-effect level (NOAEL). The U.S. Environmental Protection Agency's Office of Pesticide Programs has reviewed this study and concluded that 182 mg/kg/day was the no-observed-effect level (NOEL). The nature and relatively minor degree of effects observed in this study, as well as the absence of histopathological change in any organ even at a dose of 1002 mg/kg/day, demonstrate that the subchronic toxicity of ESA is low.
In the developmental toxicity study, the occasional occurrence of clinical observations (primarily rales) was noted in a few animals in the 1000 mg/kg/day dose group. There were no effects on body weights, body weight gains, organ weights, or food consumption. Therefore, in the absence of quantitative and definitive signs of systemic maternal toxicity, the observed clinical signs are not considered a conclusive indication of maternal toxicity. Rather, it is likely that the observed rales represented nonspecific physical trauma associated with the repeated gavage procedure with a large quantity of test chemical (in this case, a 1000 mg/kg/day dose of ESA). There were no treatment-related changes in any of the fetal parameters measured, demonstrating that intrauterine development, growth, and survival were unaffected by ESA administration. Therefore, the NOEL for maternal and developmental toxicity is considered to be 1000 mg/kg/day.
Acute administration of ESA did not induce in vivo chromosomal effects in the mouse bone marrow micronucleus assay. ESA was previously shown to be negative in Ames assays employing four strains of bacteria with and without a mammalian metabolic activation system (Kier, 1984) . The lack of effects in these studies supports the conclusion that ESA does not possess genotoxic potential.
The results of these studies, along with previously generated data, clearly indicate that the toxicity of ESA is low. Data from these studies were further evaluated to determine if additional studies were warranted. This assessment involved comparisons of: (a) ESA's toxicity to that of alachlor, for which a comprehensive toxicology database exists, and (b) no-effect levels from ESA studies in animals to anticipated levels of human exposure to understand the magnitude of margins of exposure. These evaluations are discussed below.
Comparison of ESA to Alachlor
Chemically induced effects on body weight are reliable and sensitive indicators of toxicity and can be easily compared between studies. In the 90-day study of alachlor in rats, the high-dose level (139 and 153 mg/kg/day in males and females, respectively) produced a progressive decrease in body weight gain in both sexes which was approximately 14% below controls by the end of the study (Monsanto, 1966) . The total body weight gain in high-dose (1002 mg/ kg/day) ESA-treated rats was approximately 12% below controls. Thus, the dose producing a similar effect on body weight gain was approximately seven times higher for ESA. The NOEL in the subchronic alachlor study was determined to be 1.5 mg/kg/day (based on increased spleen weights at 15 mg/kg/day), compared to the NOEL of 182 mg/kg/day for ESA. Therefore, the NOEL for ESA is approximately 121 times higher than that of alachlor. Based on these com- parisons, the subchronic toxicity of the ESA metabolite is substantially lower than that of alachlor.
A comparison of the effects of ESA and alachlor on pregnant rats and their offspring also shows a significant difference in toxicity between the two compounds. In the pilot developmental toxicity study with alachlor, maternal mortality was 100 and 80% at dose levels of 1000 and 600 mg/ kg/day, respectively (Dangler and Rodwell, 1979) . In the definitive developmental toxicity study, alachlor was administered at doses of 50, 150, and 400 mg/kg/day during Gestation Days 6-19 (Tasker and Rodwell, 1980) . In the 400 mg/ kg/day dose group, there was a slight reduction in fetal body weights (6% below control) and a slight increase in postimplantation loss; in addition, four dams died and maternal body weight gain during the dosing period was substantially reduced (39% below control). Based on these effects, the NOEL for maternal and fetal toxicity is 150 mg/kg/day. In contrast, none of these adverse effects occurred in pregnant rats or their offspring in the ESA study even at the limit dose of 1000 mg/kg/day, indicating that alachlor is substantially more toxic than its ESA metabolite. It does not appear that the longer dosing period in the alachlor studies contributed significantly to the observed difference in toxicity, since all deaths at 600 and 1000 mg/kg/day occurred by Gestation Day 15; the reduction in maternal body weight gain at 400 mg/kg/day during Gestation Days 6-16 was much more severe (70% below controls) than that observed during Days 16-20 (13% below controls).
Comparison of ESA Toxicity to Human Exposure
The relative risk associated with exposure to a chemical can be assessed by comparing no-observed-effect levels from animal studies to estimates of human exposure. The predominant route of potential human exposure to ESA is ingestion of drinking water from private wells in agricultural areas. Therefore, minute amounts of ESA which may be consumed via uptake of this soil metabolite into some agricultural products are not considered in this analysis. A groundwater survey recently conducted in southern Wisconsin provides good estimates of ESA concentrations in wells most at risk (Wisconsin DATCP, 1994) . In that survey, private wells were selected in areas of the state with the highest alachlor use. These wells represented a subset of 2500 previously sampled wells and were selected because they either had a previous detection of atrazine or alachlor or had an elevated level of nitrate. Such a selection protocol maximized the chance of detecting ESA. The survey was not designed to provide unbiased results, but rather to provide a worst-case exposure analysis. It is worth noting that the nitrate level in most of the selected wells exceeded 10 ppm, the maximum contaminant level established by EPA, and continued use of these wells should be questioned regardless of possible ESA levels. ESA was detected in 206 of the 669 selected vulnerable wells at concentrations ranging from 1.09 to 26.7 ^g/liter (limit of detection = 1.0 /xg/liter). The average concentration for the 206 detections was 4.89 ngj liter. The range of concentrations measured in the Wisconsin study was like that found in a similar study in shallow Indiana wells (Baker, 1994) . To assess the relative risk associated with exposure to ESA, margins of exposure (MOE) were calculated by dividing the NOELs from the subchronic and developmental toxicity studies by a high estimate of human exposure. A value of 13.6 /xg/liter was selected as a reasonable point estimate of worst-case exposure, since 95% of the 206 ESA detections in the 669 Wisconsin wells most at risk occurred at or below this level. The selection of 13.6 /xg/liter as a worst-case exposure is consistent with other results. In a U.S. Geological Survey (USGS) study of near surface aquifers in the midwest, the highest ESA level detected was 4.95 /jg/liter . In another USGS study, the 95th percentile ESA concentration in surface water reservoirs was 10 /j,g/ liter . MOE values were calculated separately for NOELs from both the subchronic and the developmental toxicity studies to allow independent assessments for different endpoints. The resulting margins of exposure are very high, ranging from > 133,000 to >2,500,000 (Table 7) . This indicates that the metabolite has negligible potential to produce adverse subchronic and developmental effects in humans.
These MOE values can also be used to evaluate potential risks in a broader context. The use of expanded MOEs, or "safety factors" (i.e., >100), has been widely adopted by regulatory agencies and other groups to extrapolate from noeffect levels in animals to an acceptable level of human exposure when a complete toxicology database is not available. The U.S. EPA Office of Drinking Water has used a total "uncertainty" factor of 1000 in establishing a reference dose (RfD) or health advisory for a chemical that has a limited or incomplete toxicology database (Ohanian, 1989) . A review of decisions made by the Joint FAO/WHO Expert Committee on Food Additives shows that safety factors ranging from 350 to 2000 have been used to establish acceptable daily intakes (ADI) based on subchronic animal study results (Johannsen, 1990) . A 2000-fold safety factor has also been suggested by the U.S. FDA Center for Food Safety and Applied Nutrition in establishing ADIs when only one species subchronic data are available (Rodericks et al, 1987) . The margins of exposure for ESA are still considerably larger than these safety factor values, thereby providing a regulatory basis for concluding that the risk associated with low-level ESA exposure is negligible. While this analysis is not intended to be a comprehensive risk assessment, the results clearly indicate that ESA is unlikely to produce adverse health effects. CONCLUSIONS Genotoxicity studies have not shown any evidence of DNA damage. Subchronic administration produced significant adverse effects only at an extremely high dose; most of the findings were thought to be related to decreased palatability of the drinking water. ESA did not produce any adverse effects in pregnant rats or their offspring even at the limit dose of 1000 mg/kg/day. These findings show that the subchronic and developmental toxicity of the metabolite is low. Moreover, results from these and other studies have shown that the toxicity of ESA is considerably lower than that of the parent material, alachlor. The margins of exposure for ESA are very high, indicating that this metabolite poses little risk of producing adverse effects in humans at the very low levels occasionally encountered. These results support the conclusion that ESA is not of toxicological concern, as determined by the U.S. EPA Office of Pesticide Programs (U.S. EPA, 1992) . None of the study findings or evaluations indicate that ESA should be given a priority for additional testing.
